Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q969R5
UPID:
LMBL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q969R5; Q8TEN1; Q96SC4; Q9BQI2; Q9UGS4
Background:
Lethal(3)malignant brain tumor-like protein 2 is a putative Polycomb group (PcG) protein, involved in maintaining the transcriptionally repressive state of genes through chromatin modification. It binds to monomethylated and dimethylated 'Lys-20' on histone H4 and histone H3 peptides monomethylated or dimethylated on 'Lys-4', 'Lys-9', or 'Lys-27'.
Therapeutic significance:
Understanding the role of Lethal(3)malignant brain tumor-like protein 2 could open doors to potential therapeutic strategies.